Lexicon Pharmaceuticals, Inc. LXRX
1.87 USD +0.01 (+0.54%)
At closeNov 11, 2026, 4:00 PM EST
1.95 +0.08 +4.28%
After hours · Nov 11, 4:00 PM ET
1.85 Day range 1.92
1.10 52-week range 2.68
- YTD
- +62.61%
- 1 year
- +21.43%
News
globenewswire.com Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London THE WOODLANDS, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a leading cardiometabolic biopharmaceutical company, today announced that Company management will…
benzinga.com Citigroup Maintains Buy on Lexicon Pharmaceuticals, Raises Price Target to $3.4 Citigroup analyst Yigal Nochomovitz maintains Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Buy and raises the price target from $3.1 to $3.4.
benzinga.com Lexicon Pharma Presents New Data Highlighting Cardiovascular Effects Of Dual SGLT1/2 Inhibitor, Sotagliflozin, At AHA Scientific Sessions 2026 -- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions ---- Study in living human heart tissue…
globenewswire.com New Data at 2026 American Heart Association Scientific Sessions Highlight Cardiovascular Effects of Sotagliflozin on Thrombus Formation and in Hypertrophic Cardiomyopathy -- In a randomized crossover study, sotagliflozin significantly reduced ex vivo thrombus formation from baseline under both arterial and venous flow conditions -- -- Study in living human heart…
seekingalpha.com Lexicon Pharmaceuticals, Inc. (LXRX) Q3 2026 Earnings Call Transcript Lexicon Pharmaceuticals, Inc. ( LXRX ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Lisa DeFrancesco - Senior Vice President of Investor Relations & Corporate…
marketbeat.com What Lexicon Pharmaceuticals (LXRX) Said on Its Q3 Earnings Call Lexicon Pharmaceuticals NASDAQ: LXRX expects two key milestones in the first quarter of 2027: results from a pivotal heart disease trial and a resubmission of its application for a type 1 diabetes…
zacks.com Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue Estimates Lexicon Pharmaceuticals (LXRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.04 per share a year ago.
benzinga.com Lexicon Pharmaceuticals Q3 2026 Earnings Call Transcript Lexicon Pharmaceuticals (NASDAQ:LXRX) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide…
benzinga.com Lexicon Pharmaceuticals Q3 EPS $(0.03) Beats $(0.06) Estimate, Sales $11.250M Beat $4.142M Estimate Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.06) by 50 percent. This is a 25 percent increase over losses of…
globenewswire.com Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical Updates Phase 3 SONATA-HCM study substantially overenrolled; top-line data expected Q1 2027 Positive STENO1 safety data strengthens benefit-risk profile for ZYNQUISTA® NDA resubmission Phase 1 clinical…
benzinga.com Lexicon Pharmaceuticals Issues Update On Baseline Characteristics Of Patients Randomized Into Its Ongoing Pivotal Phase 3 SONATA-HCM Clinical Trial Evaluating Sotagliflozin In Patients With Symptomatic Hypertrophic Cardiomyopathy; Patient Enrollment Profile Of SONATA-HCM Is Consistent With Study’s Inclusive Design Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a leading cardiometabolic biopharmaceutical company, today provided an update on the baseline characteristics of the patients randomized into the ongoing…
benzinga.com Lexicon Highlights Preclinical Studies Showing Biological Effects Of Sotagliflozin In Hypertrophic Cardiomyopathy And Thrombotic Disease Pathways -- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy ---- Second preclinical study shows inhibitory effects of…
benzinga.com Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript Lexicon Pharmaceuticals (NASDAQ:LXRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.…
benzinga.com This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday Analysts initiate coverage: Buy on IonQ ($60), Jack Henry ($193) and 10X Genomics ($110); Overweight Lexicon ($8); In-Line Fortive ($60).- benzinga.com Cantor Fitzgerald Initiates Coverage On Lexicon Pharmaceuticals with Overweight Rating, Announces Price Target of $8 Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Lexicon Pharmaceuticals (NASDAQ:LXRX) with a Overweight rating and announces Price Target of $8.
benzinga.com Beta Bionics, J.B. Hunt Transport And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session U.S. stock futures rose, but Beta Bionics fell 7.1% after pricing a stock offering; several other stocks also declined in premarket trading.- benzinga.com Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket Tempest shares surged 49.6% on a Senlang CD7 CAR-T option deal, while several small-cap stocks posted sharp premarket gains and losses.
benzinga.com Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate Lexicon Pharmaceuticals (NASDAQ:LXRX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 800 percent decrease over earnings…- benzinga.com Lexicon Pharmaceuticals Completes Randomization Of Patients In Its Pivotal Phase 3 'Sotagliflozin In Patients With Symptomatic Obstructive And Non-Obstructive Hypertrophic Cardiomyopathy' Clinical Trial The study substantially exceeded its enrollment target of 500 patients across more than 130 sites in 20 countries. The primary efficacy endpoint will assess improvement in symptoms for the entire…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session 
benzinga.com Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures up, Dow gains 150 points. Avis Budget Group (CAR) shares fall 9.6% in pre-market. Other stocks lower in pre-market trading.
benzinga.com Earnings Scheduled For March 5, 2026 
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com Progress Software Posts Upbeat Q4 Earnings, Joins ServisFirst Bancshares, Zura Bio And Other Big Stocks Moving Higher On Wednesday 
benzinga.com Tilray Brands, SuperX AI Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session 
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1…- benzinga.com Earnings Scheduled For August 6, 2025
- benzinga.com Earnings Scheduled For May 13, 2025
benzinga.com US Stocks Likely To Open Lower After 3-Day Fall: 'Equity Drawdown Probability Hasn't Peaked Yet,' Says Goldman Sachs Analyst U.S. stock futures fell on Monday after three consecutive days of decline on Friday. Futures of benchmark indices were lower in premarket.- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com Earnings Scheduled For March 6, 2025
- benzinga.com Earnings Scheduled For November 12, 2024
- benzinga.com Crude Oil Moves Higher; Apple Shares Slide After Q4 Results
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
- benzinga.com Nasdaq Surges Over 200 Points; Amazon Shares Jump After Strong Results
- benzinga.com Dow Jumps 400 Points; US Adds 12,000 Jobs In October
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
benzinga.com Why DoorDash Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket - benzinga.com Intel Reports Weak Results, Joins Amazon, Opendoor Technologies And Other Big Stocks Moving Lower In Friday's Pre-Market Session
- benzinga.com Aaron's, Mirum Pharmaceuticals, Primo Water And Other Big Stocks Moving Higher On Monday
- benzinga.com Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.
- benzinga.com Earnings Scheduled For November 8, 2023 Companies Reporting Before The Bell • Flex LNG (NYSE:FLNG) is estimated to report earnings for its third quarter.
- benzinga.com Why Immunic Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket Gainers SuperCom Ltd. (NASDAQ: SPCB) shares rose 78.4% to $0.6425 in pre-market trading, after falling 13% on Monday.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 647 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday During the session on Thursday, 461 stocks hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's session, 275 companies made new 52-week lows.